Matheson recently advised Horizon Therapeutics ("Horizon") on its acquisition of EirGen Pharma's ("EirGen") manufacturing facility in County Waterford. As a result of the deal, valued at over $65 million, Horizon will make its first move into direct manufacturing. The transaction will also see a number of EirGen's employees transfer to Horizon, and the creation of a further 50 new roles over the next 18 months.
A cross-departmental Matheson team worked on the transaction, including Corporate M&A partner David Fitzgibbon, Commercial Real Estate partner Sally Anne Stone and Corporate M&A associate, John Coary.
As a result of the acquisition, Horizon will acquire the 44,000 square foot EirGen manufacturing facility. The transaction, which is subject to customary closing conditions, is expected to close in the third quarter of 2021 and will be a significant boost to the Life Science ecosystem in the South East.
Commenting on the deal, Corporate M&A partner David Fitzgibbon said; "This acquisition is a key component of Horizon's future international growth strategy, providing essential in-house manufacturing capability for the business. We are proud to advise Horizon on this important acquisition and we wish them every success in the future."
If you would like any further information, please contact a member of our Corporate M&A team today.
